REGN 📈 Regeneron Pharmaceuticals - Overview

Regeneron Pharmaceuticals, Inc. is a biotechnology company that engages in the discovery, development, and commercialization of innovative medicines to treat a wide range of diseases globally. The company's product portfolio includes EYLEA injection, which is used to treat various eye disorders such as wet age-related macular degeneration, diabetic macular edema, and myopic choroidal neovascularization. Additionally, EYLEA is used to treat diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity, showcasing the company's commitment to addressing complex ophthalmic conditions.

Regeneron's pipeline also includes Dupixent injection, which is designed to treat atopic dermatitis and asthma in adults and pediatric patients. This highlights the company's focus on addressing allergic and inflammatory diseases. Furthermore, the company offers Libtayo injection for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, demonstrating its efforts in oncology. Praluent injection is another key product, used to treat heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults, underscoring the company's presence in the cardiovascular and metabolic disease space.

The company has also developed REGEN-COV, a treatment for COVID-19, and Kevzara solution for rheumatoid arthritis in adults. Its product lineup is further complemented by Inmazeb injection, used to treat infections caused by Zaire ebolavirus, and ARCALYST injection for cryopyrin-associated periodic syndromes. ZALTRAP injection is another product, used for the treatment of metastatic colorectal cancer. Regeneron's extensive research and development efforts are aimed at creating new therapies for patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases, as well as cancer, pain, and hematologic conditions.

Regeneron has established strategic collaborations to advance its pipeline. For instance, it has partnered with Mammoth Biosciences, Inc. to research, develop, and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company has also collaborated with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. Founded in 1988 and headquartered in Tarrytown, New York, Regeneron Pharmaceuticals, Inc. is listed on the NASDAQ under the ticker symbol REGN, with its common stock classified under the GICS Sub Industry: Biotechnology.